Selective Glucocorticoid Receptor Modulators of Immune Checkpoint Function.

Area of Science:

• Immunology
• Pharmacology
• Structural Biology

Background:

• Glucocorticoids (GCs) regulate immunity, inflammation, and metabolism via the glucocorticoid receptor (GR).
• Current GC therapies are limited by side effects, hindering the design of safer, selective drugs.
• Linking specific ligand-GR structural states to distinct biological outcomes remains a challenge.

Purpose of the Study:

• To design selective glucocorticoid receptor modulators (SGRMs) with improved immunomodulatory profiles.
• To elucidate the allosteric mechanisms underlying GR modulation by SGRMs.
• To develop a framework for rational drug design of targeted immunotherapies.

Main Methods:

• Structure-based drug design to create SGRMs by modifying steroidal scaffolds.
• Molecular dynamics simulations to analyze ligand-receptor interactions and allosteric effects.
• A ligand perturbation with machine learning (LPML) framework to map cellular responses.

Main Results:

• SGRMs suppressed T cell pro-inflammatory cytokines and promoted memory T cell differentiation.
• SGRMs demonstrated minimal induction of M2 macrophage polarization and T cell checkpoint proteins (PD-1, CTLA-4).
• Molecular dynamics revealed substituents acting as a lever arm to allosterically tune GR activity.
• LPML identified effector T cell gene networks linked to immune checkpoint induction.

Conclusions:

• SGRMs represent a novel class of immunomodulators with potential for targeted anti-inflammatory therapies.
• The study decodes the logic of allosteric drug action for rational SGRM design.
• This approach enables the development of SGRMs with tailored immunomodulatory effects.